An Inside Examination Of Strategies In Solar Generator System Vs Products Inc

solar generator system

The company is targeting adjusted earnings-per-share growth of 12% or more through 2020. It's planning to accomplish this goal in part by increasing sales of QuantiFERON-TB and by capturing at least 20% of the oncology benchtop sequencing market share for GeneReader NGS. Better buy I suspect that Qiagen might be able to deliver on its goals, which would likely push the stock higher. However, my vote between these two stocks goes to Opko. The 20% drop in Opko's value following the disappointing clinical results for hGH-CTP provides a good opportunity for a rebound. While there's definitely a risk that more bad news for the human growth hormone could weigh the stock down, I think the company has enough irons in the fire that something will serve as a positive catalyst this year to send shares higher. 10 stocks we like better than Opko Health When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Opko Health wasn't one of them! That's right -- they think these 10 stocks are even better buys.

For the original version including any supplementary images or video, visit

(visit site)

VS Products Inc

You may also be interested to read